Lineage Cell Therapeutics, Inc. (LCTX)
After hours:
| Previous close | 1.0500 |
| Open | 1.0900 |
| Bid | 1.0600 x 3200 |
| Ask | 1.0600 x 1200 |
| Day's range | 1.0500 - 1.1200 |
| 52-week range | 0.8400 - 1.6100 |
| Volume | |
| Avg. volume | 947,408 |
| Market cap | 200.126M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.20 |
Business WireLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
CARLSBAD, Calif., May 02, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific T
Business WireLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
CARLSBAD, Calif., April 30, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM), to support the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS builds upon a successful inaugural event held in 2023 and will co
Business WireLineage Announces Changes to Board of Directors
CARLSBAD, Calif., April 29, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogen
